Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study

Authors :: Hella Danoe
Thomas Jensen
Erik Jakobsen
Vesna Glavicic
Jurij Bogovic
Dorte Nielsen
Eva Balslev
Annie Rasmussen
Peter Buhl Jensen
AS Knoop
Bent Ejlertsen
Ida Kappel Buhl
Ulrik Lassen
Joergen Hansen
Ulla Hald Buhl
Sven Tyge Langkjer
Steen Knudsen
Anker Jon Hansen
Mogens Winkel Madsen
Soeren Linnet
Source :: Hugger Jakobsen, E, Nielsen, D, Danø, H, Linnet, S, Hansen, J, Lassen, U N, Balslev, E, Glavicic, V, Bogovic, J, Knudsen, S, Ejlertsen, B, Søegaard Knoop, A, Buhl, U H, Madsen, M W, Buhl, I K, Hansen, A, Jensen, T, Rasmussen, A, Jensen, P B & Langkjer, S T 2018, ' Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study ', Journal of Clinical Oncology, vol. 36, no. 15 Suppl., e13077 . https://doi.org/10.1200/JCO.2018.36.15_suppl.e13077
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e13077Background: In an ongoing, open-label Phase 2 study liposomal cisplatin (LiPlaCis) was evaluated in metastatic breast cancer (mBC) patients selected by a cisplatin-specific mRNA-based drug re...

Full Text Access

Tools